We are the voice of the home and alternate site infusion
community and the patients we serve

Fixing the Part B HIT Services Benefit

While Congress intended to create a comprehensive Medicare home infusion benefit for Part B DME drugs in the 21st Century Cures Act, flawed implementation by CMS has led to major access issues for Medicare beneficiaries.

Closing the Part D Coverage Gap

Medicare’s coverage of home infusion therapy is limited. Only about 40 drugs therapies are covered under the Part B DMEPOS benefit, leaving the vast majority of home infused-drugs covered by Part D prescription drugs plan.

Commercial Payor Advocacy

NHIA has developed recommendations for commercial, Medicaid and Medicare Advantage payors to reduce administrative burden and remove barriers to accessing certain infusion services.

NHIA represents and advances the interests of organizations that provide medically necessary infusion therapies and products to patients in alternate sites of care. As part of the association’s efforts to advance the industry, we monitor and advocate on a range of important health care issues. We are focused on clinical and business best-practices that may be subject to legislation, regulation, accreditation, practices of health plans/third party payers, and more. Learn more about the issues impacting home and alternate site infusion and how to use your voice to ensure all patients have access to high quality infusion services so they can lead healthy, independent lives.

Latest Advocacy News